Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial

Lancet

Volumn 354, Issue 9180, 1999, Pages 716-722

  Van de Werf, F ^a   Adgey, J ^a   Ardissino, D ^a   Armstrong, P W ^a   Aylward, Ph ^a   Barbash, G ^a   Betriu, A ^a   Binbrek, A S ^a   Califf, R ^a   Diaz, R ^a   Fanebust, R ^a   Fox, K ^a   Granger, C ^a   Heikkila, J ^a   Husted, S ^a   Jansky, P ^a   Langer, A ^a   Lupi, E ^a   Maseri, A ^a   Meyer, J ^a   Mlczoch, J ^a   Mocceti, D ^a   Myburgh, D ^a   Oto, A ^a   Paolasso, E ^a   Pehrsson, K ^a   Seabra Gomes, R ^a   Soares Piegas, L ^a   Sugrue, D ^a   Tendera, M ^a   Topol, E ^a   Toutouzas, P ^a   Vahanian, A ^a   Verheugt, F ^a   Wallentin, L ^a   White, H ^a   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; HEPARIN; TENECTEPLASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033612881     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)07403-6     Document Type: Article

References (14)

1. White H.D., Van de Werf F.J. Thrombolysis for acute myocardial infarction. Circulation. 97:1998;1632-1646.
2. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 337:1997;1118-1123.
3. Keyt B.A., Paoni N.F., Refino C.J.et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 91:1994;3670-3674.
4. Cannon C.P., McCabe C.H., Gibson C.M.et al. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 95:1997;351-356.
5. Cannon C.P., Gibson C.M., McCabe C.H.et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation. 98:1998;2805-2814.
6. Van de Werf F., Cannon C.P., Luyten A.et al. Safety assessment of single bolus administration of TNK-tPA in acute myocardial infarction: the ASSENT-I trial. Am Heart J. 137:1999;786-791.
7. Jones B., Jarvis P., Lewis J.A., Ebbutt A.F. Trials to assess equivalence: the importance of rigorous methods. BMJ. 313:1996;36-39.
8. Ware A.M., Antman E.M. Equivalence trials. N Engl J Med. 337:1997;1159-1161.
9. White H.D. Thrombolytic therapy and equivalence trials. J Am Coll Cardiol. 31:1998;494-496.
10. Koch G.G., Tangers C.M., Jung J.W., Amora I.A. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Stat Med. 17:1998;1863-1892.
11. Lee K.L., Woodlief L.H., Topol E.J.et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation. 91:1995;1659-1668.
12. Chesebro J.H., Knatterud G., Roberts R. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation. 76:1987;142-154.
13. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 336:1990;71-75.
14. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.